Indegene Q4 FY26 Revenue Crosses Rs 1,000 Crore Mark

Indegene Q4 FY26 revenue crossed a major milestone, but profits told a different story.

The company reported revenue of Rs 1,003 crore for the quarter, marking a strong 32.8 percent year-on-year growth and its first time breaching the Rs 1,000 crore mark.

Despite this surge, net profit fell sharply by around 32 percent to Rs 79.7 crore, reflecting pressure on margins.

The drop in profit came as costs rose faster than revenue. While the company continued to expand its business, operating margins narrowed significantly during the quarter. Increased spending on talent, technology, and expansion efforts weighed on overall profitability, even as topline growth remained strong.

Also Read: How Emerging Biotech Startups Reshaping the Bioprocessing Future

A key factor behind the decline was higher expenses related to acquisitions. Indegene has been actively investing in inorganic growth, and integration costs from these deals impacted earnings in the short term. This strategy is aimed at strengthening capabilities and scaling operations, but it has added near-term financial pressure.

At the operating level, EBITDA growth lagged behind revenue growth, further highlighting margin compression. The company’s EBITDA margin declined compared to the same period last year, signaling that efficiency has taken a hit amid aggressive expansion.

For the full financial year FY26, Indegene reported solid performance with revenue reaching around Rs 3,510 crore, up 23.6 percent year-on-year. The company also saw healthy growth in cash flows, indicating underlying business strength despite profit challenges in the latest quarter.

The Indegene Q4 FY26 revenue performance reflects a company in growth mode, prioritizing scale and capability building over immediate profitability. Going forward, investors will closely watch whether margins stabilize and profits begin to align with the strong revenue trajectory.